Coverage
Filings
| Filing | Date |
|---|---|
| AstraZeneca settles Nexium liability litigations | 3 Oct 2023 |
| Total Voting Rights | 2 Oct 2023 |
| Dato-DXd improved PFS in breast cancer | 22 Sept 2023 |
| Alexion completes Pfizer gene therapy agreement | 20 Sept 2023 |
| Enhertu recommended in EU for HER2-mutant NSCLC | 15 Sept 2023 |
| Fasenra Phase III EGPA trial met primary endpoint | 11 Sept 2023 |
| Update on US review of Ultomiris for NMOSD | 6 Sept 2023 |
| Total Voting Rights |
AstraZeneca PLC said its lupus drug Saphnelo succeeded in a late-stage trial for a new, self-injectable formulation, a positive development for the company's drug pipeline.
AstraZeneca PLC said its drug Fasenra failed to meet the main goal of a late-stage trial aimed at treating chronic obstructive pulmonary disease, or COPD, marking another recent setback for the drugmaker's development pipeline.
AstraZeneca PLC said its experimental drug for a rare disease failed to meet the main goal of a late-stage study, a setback for its growing rare disease business.
AstraZeneca PLC said its experimental drug baxdrostat succeeded in a late-stage trial for treating patients with hard-to-control high blood pressure, a common condition that has seen little therapeutic innovation in decades.
| 1 Sept 2023 |
| Total Voting Rights | 1 Aug 2023 |
| Half-year Report | 28 Jul 2023 |
| Alexion enters gene therapy agreement with Pfizer | 28 Jul 2023 |
| Beyfortus approved in US for infant RSV prevention | 17 Jul 2023 |